Amphista Reveals AMX-883 Preclinical Data for AML Therapy
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia Amphista Therapeutics, a leader in...